BR112022009254A2 - Agentes antissenso il-34 e métodos de usar os mesmos - Google Patents

Agentes antissenso il-34 e métodos de usar os mesmos

Info

Publication number
BR112022009254A2
BR112022009254A2 BR112022009254A BR112022009254A BR112022009254A2 BR 112022009254 A2 BR112022009254 A2 BR 112022009254A2 BR 112022009254 A BR112022009254 A BR 112022009254A BR 112022009254 A BR112022009254 A BR 112022009254A BR 112022009254 A2 BR112022009254 A2 BR 112022009254A2
Authority
BR
Brazil
Prior art keywords
methods
fibrosis
disclosed
inflammatory diseases
antisense agents
Prior art date
Application number
BR112022009254A
Other languages
English (en)
Inventor
Viti Francesca
MCNULTY Marie
Bellinvia Salvatore
Original Assignee
Nogra Pharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nogra Pharma Ltd filed Critical Nogra Pharma Ltd
Publication of BR112022009254A2 publication Critical patent/BR112022009254A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1136—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against growth factors, growth regulators, cytokines, lymphokines or hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/321—2'-O-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/323—Chemical structure of the sugar modified ring structure
    • C12N2310/3231—Chemical structure of the sugar modified ring structure having an additional ring, e.g. LNA, ENA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/33—Chemical structure of the base
    • C12N2310/334—Modified C
    • C12N2310/3341—5-Methylcytosine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/34—Spatial arrangement of the modifications
    • C12N2310/346—Spatial arrangement of the modifications having a combination of backbone and sugar modifications

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Endocrinology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Plant Pathology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

AGENTES ANTISSENSO IL-34 E MÉTODOS DE USAR OS MESMOS. São revelados aqui inibidores de IL-34, incluindo sequências oligonucleotídicas antissenso de IL-34, e métodos para tratar doenças inflamatórias, como uma doença inflamatória intestinal, e/ou fibrose, associadas com atividade elevada ou a expressão de IL-34. Também são reveladas composições farmacêuticas contendo um inibidor de IL-34, por exemplo, um oligonucleotídeo antissenso de IL-34, útil para tratamento de doenças inflamatórias e/ou fibrose e fabricação de medicamentos contendo um inibidor de IL-34 revelado para ser usado no tratamento de doenças inflamatórias e/ou fibrose.
BR112022009254A 2019-11-15 2020-11-16 Agentes antissenso il-34 e métodos de usar os mesmos BR112022009254A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962935819P 2019-11-15 2019-11-15
PCT/EP2020/082281 WO2021094616A1 (en) 2019-11-15 2020-11-16 Il-34 antisense agents and methods of using same

Publications (1)

Publication Number Publication Date
BR112022009254A2 true BR112022009254A2 (pt) 2022-10-04

Family

ID=73455726

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022009254A BR112022009254A2 (pt) 2019-11-15 2020-11-16 Agentes antissenso il-34 e métodos de usar os mesmos

Country Status (10)

Country Link
US (1) US20230002770A1 (pt)
EP (1) EP4058575A1 (pt)
JP (1) JP2023503804A (pt)
KR (1) KR20220098231A (pt)
CN (1) CN114729363A (pt)
AU (1) AU2020384935A1 (pt)
BR (1) BR112022009254A2 (pt)
CA (1) CA3157306A1 (pt)
MX (1) MX2022005900A (pt)
WO (1) WO2021094616A1 (pt)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022243299A1 (en) * 2021-05-17 2022-11-24 Nogra Pharma Limited Il-34 antisense agents and methods of using same

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2009315898B2 (en) 2008-11-13 2015-07-23 Nogra Pharma Limited Antisense compositions and methods of making and using same
KR20150104275A (ko) * 2014-03-05 2015-09-15 울산대학교 산학협력단 비만 관련 질환의 진단과 치료를 위한 il-34의 용도
MA44309A (fr) * 2015-11-25 2018-10-03 Nogra Pharma Ltd Oligonucléotides antisens il-34 et leurs procédés d'utilisation

Also Published As

Publication number Publication date
KR20220098231A (ko) 2022-07-11
US20230002770A1 (en) 2023-01-05
CA3157306A1 (en) 2021-05-20
EP4058575A1 (en) 2022-09-21
CN114729363A (zh) 2022-07-08
WO2021094616A1 (en) 2021-05-20
AU2020384935A1 (en) 2022-06-09
JP2023503804A (ja) 2023-02-01
MX2022005900A (es) 2022-06-24

Similar Documents

Publication Publication Date Title
BR112022002581A2 (pt) Inibidores heterocíclicos de rip1 quinase
MX2021007156A (es) Inhibidores de kif18a.
MX2022001302A (es) Inhibidores de kif18a.
MX2022001181A (es) Inhibidores de kif18a.
NZ767118A (en) Modified double-stranded rna agents
NO20060906L (no) Anvendelse av RNAI-inhibiterende PARP-aktivitet for fremstilling av et medikament for behandling av cancer
BR112013028666A2 (pt) compostos de pirazolo sulfonamida tricícilos e métodos para fazer e usar o mesmo
BR112022016382A2 (pt) Triptaminas específicas para o uso no tratamento de doenças do humor
CL2020001742A1 (es) Inhibidores de glicolato oxidasa para el tratamiento de enfermedades
PH12021550605A1 (en) Farnesoid x receptor agonists and uses thereof
BR112021024463A2 (pt) Oligonucleotídeos e métodos de uso para o tratamento de doenças neurológicas
CL2021001490A1 (es) Constructos de iarn modificados químicamente y usos de estos
BR112018069930A2 (pt) agonistas de ppar, compostos, composições farmacêuticas, e métodos de uso dos mesmos
BR112016030730A8 (pt) composto
EA201892366A1 (ru) Антисмысловые олигомеры и способы их применения для лечения заболеваний, связанных с геном кислой альфа-глюкозидазы
BR112021021921A2 (pt) Agente, uso de um agente e método de tratamento ou prevenção de uma doença metabólica
CL2021001488A1 (es) Transposasa de piggybac mutada
EA201890379A1 (ru) Терапевтические олигонуклеотиды
BR112022021963A2 (pt) Inibidores macrocíclicos de peptidilarginina desiminases
BR112017001971A2 (pt) ?métodos e composições para diagnosticar e tratar distúrbios inflamatórios intestinais?
BR112022009254A2 (pt) Agentes antissenso il-34 e métodos de usar os mesmos
BR112023018237A2 (pt) Fenalquilaminas e métodos para fabricação e uso das mesmas
BR112018010736A2 (pt) oligonucleotídeos antissenso contra il-34 e métodos de uso dos mesmos
BR112015024760A2 (pt) oligonucleotídeo beta modificado para uso em um método de prevenção e/ou tratamento de uma doença oftálmica
BR112018007358A2 (pt) derivados de 1,4-dicarbonil-piperidila